Alto Neuroscience Inc (ANRO)
NYSEHealth CareBiotechnologySnapshot 2026-09-04
$35.55-2.34%
Close 2026-09-04 · 1-day change
NYSEHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ANRO
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | |
|---|---|---|---|---|---|
| Operating Expenses & Income | |||||
| R&D Expenses | 64.9 | 45.6 | 47.0 | 30.3 | — |
| Operating Income | (88.3) | (66.4) | (68.6) | (37.8) | — |
| Earnings from Continuing Operations | |||||
| Interest Expense | — | 2.5 | 1.4 | — | — |
| Interest & Investment Income | 6.8 | 6.6 | 8.9 | 2.3 | — |
| Other Non-Operating Income / Expenses | 4.0 | 3.1 | 7.2 | 1.5 | — |
| Income Tax Expense | — | — | — | 0.0 | — |
| Net Income | |||||
| Net Income | (84.2) | (63.2) | (61.4) | (36.3) | — |
| Per Share | |||||
| Basic EPS | (1.97) | (2.19) | (2.50) | (9.73) | — |
| Diluted EPS | (1.97) | (2.19) | (2.50) | (9.73) | — |
| Basic Weighted Avg Shares | 42.8 | 28.9 | 24.6 | 3.7 | — |
| Diluted Weighted Avg Shares | 42.8 | 28.9 | 24.6 | 3.7 | — |
| Supplemental | |||||
| EBITDA | — | — | (68.1) | (37.4) | — |
| EBIT | (88.3) | (66.4) | (68.6) | (37.8) | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.